AAIC 2025: Top Interviews and Key Takeaways

The 2025 Alzheimer’s Association International Conference (AAIC), held July 27 to 31 in Toronto, Ontario, Canada, gathered thousands of experts to showcase breakthroughs in Alzheimer disease research, diagnosis, and treatment. This year’s meeting highlighted rapid advances in biomarker-based detection, novel therapeutic strategies targeting amyloid and tau, and innovative tools designed to bring earlier, more accessible care to patients.

In our on-site coverage, NeurologyLive® sat down with leading voices including Elisabeth Thijssen, PhD, on Neurogen Biomarking’s home-based diagnostic ecosystem; Todd Levine, MD, on the Syn-One Test’s ability to detect neurodegenerative pathology before symptoms emerge; Fanny Elahi, MD, PhD, on the case for blood-based biomarkers; Stephen Salloway, MD, on safer, equally effective donanemab dosing; Philip Scheltens, MD, PhD, on obicetrapib’s dual cardiovascular and neuroprotective potential; Tanya Talkar, PhD, on digital acoustic metrics to capture early cognitive changes; and Diana Gallagher, MD, on Biogen’s tau-targeting therapy BIIB080. These are just a few of the expert perspectives featured in our AAIC 2025 interview series.

Click here for more coverage of Alzheimer disease from NeurologyLive^®, or more coverage of AAIC 2025, click here.